IRF5 siRNA Nanoimmunotherapy: Restoring Macrophage Efferocytosis in Atherosclerosis
Circulation · 02.12.2025 · 152 (22) · 1564-1581
DOI: 10.1161/circulationaha.125.075352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.12.2025. Verfasst von Zhongshan He und 15 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Critical Care Medicine, Anesthesiology and Translational Neuroscience Center, and Clinical Pharmacy, Frontiers Science Center for Dise…. Hauptthemen laut MEDLINE: Interferon Regulatory Factors, Atherosclerosis, Macrophages, RNA, Small Interfering. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 75 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Impaired efferocytosis of macrophages within advanced atherosclerotic plaques leads to plaque deposition and rupture, ultimately resulting in atherothrombotic events. Effective restoration of efferocytic capacity in lesional macrophages remains a challenge in atherosclerosis treatment. METHODS: We developed an engineered small interfering RNA (siRNA) nanoparticle platform that can therapeutically manipulate lesional macrophages by inhibiting an overexpressed plaque-destabilizing macrophage molecule: IRF5 . RESULTS: IRF5 siRNA (siIRF5) nanoimmunotherapeutics were efficiently taken up by lesional macrophages, particularly Cd11c + and Trem2 hi macrophages, and enhanced their phagocytic clearance of apoptotic cells by efficiently silencing IRF5 expression within these macrophage subsets in atherosclerotic plaques. This resulted in remarkable therapeutic efficacy, as evidenced by reduction of necrotic core area and enhancement of plaque stability in 2 independent ApoE −/− murine models of atherosclerosis. Single-cell RNA sequencing analysis revealed that siIRF5 nanoimmunotherapeutics increased the proefferocytic receptors while decreasing the expression of proinflammatory genes associated with cytokine and chemokine pathways in lesional macrophages. CONCLUSIONS: These findings highlight the potential of siRNA nanoimmunotherapeutics for treating atherosclerosis and other diseases resulting from impaired efferocytosis in macrophages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Critical Care Medicine, Anesthesiology and Translational Neuroscience Center, and Clinical Pharmacy, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy and…
- Department of Hepatology, Beijing Youan Hospital, Capital Medical University, China (Z.D.).
- Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for HIV/AIDS Research, Central Laboratory, Beijing Youan Hospital, Capital Medical University, China (B.S.).
- Key Laboratory of Green Chemistry and Technology (Ministry of Education), College of Chemistry (Y.G., J.Z.), Sichuan University.
- Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (Y. Li, Z.Z., D.Q., W.C.).
ORCID-Profile: Zhongshan He, Bin Su, Wanqin Zeng, Yu Guo, Yongjiang Li, Haixing Shi, Chunling Jiang, Ji Zhang, Yan Kang, Wei Chen
Zitieren
APA
He, Z., Luo, Y., Duan, Z., Su, B., Zeng, W., Guo, Y., Li, Y., He, X., Shi, H., Zhou, Z., Jiang, C., Qin, D., Zhang, J., Kang, Y., Chen, W., & Song, X. (2025). IRF5 siRNA Nanoimmunotherapy: Restoring Macrophage Efferocytosis in Atherosclerosis. Circulation, 152(22), 1564-1581. https://doi.org/10.1161/circulationaha.125.075352
Vancouver
He Z, Luo Y, Duan Z, Su B, Zeng W, Guo Y, et al. IRF5 siRNA Nanoimmunotherapy: Restoring Macrophage Efferocytosis in Atherosclerosis. Circulation. 2025;152(22):1564-1581. doi:10.1161/circulationaha.125.075352
BibTeX
@article{He2025,
author = {He, Zhongshan and Luo, Yaoyao and Duan, Zhonghui and Su, Bin and Zeng, Wanqin and Guo, Yu and Li, Yongjiang and He, Xi and Shi, Haixing and Zhou, Zhuoming and Jiang, Chunling and Qin, Duotian and Zhang, Ji and Kang, Yan and Chen, Wei and Song, Xiangrong},
title = {IRF5 siRNA Nanoimmunotherapy: Restoring Macrophage Efferocytosis in Atherosclerosis},
journal = {Circulation},
year = {2025},
volume = {152},
number = {22},
pages = {1564--1581},
doi = {10.1161/circulationaha.125.075352}
}
EUVIMED